# Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response

> **NCT02471469** · — · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide, 160mg, 40 mg soft capsules, once daily

## Key facts

- **NCT ID:** NCT02471469
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-08-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471469, "Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02471469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*